128 related articles for article (PubMed ID: 37519418)
1. Health Care Resource Use Among Patients with Advanced Non-Small Cell Lung Cancer in Japan, 2017-2019.
Goto Y; Kawamura K; Fukuhara T; Namba Y; Aoe K; Shukuya T; Tsuda T; Santorelli ML; Taniguchi K; Kamitani T; Irisawa M; Kanda K; Abe M; Burke T; Nokihara H
Curr Ther Res Clin Exp; 2023; 99():100712. PubMed ID: 37519418
[TBL] [Abstract][Full Text] [Related]
2. Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan.
Nokihara H; Kijima T; Yokoyama T; Kagamu H; Suzuki T; Mori M; Santorelli ML; Taniguchi K; Kamitani T; Irisawa M; Kanda K; Abe M; Burke T; Goto Y
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740512
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study.
Lee DH; Isobe H; Wirtz H; Aleixo SB; Parente P; de Marinis F; Huang M; Arunachalam A; Kothari S; Cao X; Donnini N; Woodgate AM; de Castro J
BMC Health Serv Res; 2018 Mar; 18(1):147. PubMed ID: 29490654
[TBL] [Abstract][Full Text] [Related]
5. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
[TBL] [Abstract][Full Text] [Related]
6. Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
Yoshimura A; Takeda T; Kataoka N; Tanimura K; Fukui M; Chihara Y; Takei S; Kawachi H; Nakanishi K; Yamanaka Y; Tamiya N; Honda R; Okura N; Yamada T; Uryu K; Murai J; Shiotsu S; Yoshioka H; Yamada T; Kurata T; Takayama K
Front Oncol; 2024; 14():1303543. PubMed ID: 38344209
[TBL] [Abstract][Full Text] [Related]
7. Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
Wang F; Mishina S; Takai S; Le TK; Ochi K; Funato K; Matsuoka S; Ohe Y
Clin Ther; 2017 Jun; 39(6):1146-1160. PubMed ID: 28527959
[TBL] [Abstract][Full Text] [Related]
8. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
[No Abstract] [Full Text] [Related]
9. Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis.
Qiu L; Gao S; Du S; Sun S; Liang Y; Sun Z; Li T; Jia G; Li K; Sun X; Jiao S; Zhao X
Front Oncol; 2022; 12():974227. PubMed ID: 36523994
[TBL] [Abstract][Full Text] [Related]
10. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
12. Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.
Wolf A; Stratmann JA; Shaid S; Niklas N; Calleja A; Ubhi H; Munro R; Waldenberger D; Carroll R; Daumont MJ; Penrod JR; Lacoin L; Rohde G
BMC Pulm Med; 2023 Jan; 23(1):16. PubMed ID: 36639770
[TBL] [Abstract][Full Text] [Related]
13. Platinum-combination chemotherapy with or without immune-checkpoint inhibitor in patients with postoperative recurrent non-small cell lung cancer previously treated with adjuvant platinum-doublet chemotherapy: A multicenter retrospective study.
Hisakane K; Tozuka T; Takahashi S; Taniuchi N; Nishijima N; Atsumi K; Okano T; Seike M; Hirose T
Thorac Cancer; 2023 Jul; 14(21):2069-2076. PubMed ID: 37290434
[TBL] [Abstract][Full Text] [Related]
14. Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis.
Vanderpoel J; Emond B; Ghelerter I; Milbers K; Lafeuille MH; Lefebvre P; Ellis LA
Pharmacoecon Open; 2023 Jul; 7(4):617-626. PubMed ID: 37074589
[TBL] [Abstract][Full Text] [Related]
15. Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.
Liu T; Wu S; Fang W; Li H; Su L; Qi G; Li H; Liu Y
PLoS One; 2023; 18(4):e0283719. PubMed ID: 37071610
[TBL] [Abstract][Full Text] [Related]
16. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
17. Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment.
Ramagopalan SV; Popat S; Gupta A; Boyne DJ; Lockhart A; Hsu G; O'Sullivan DE; Inskip J; Ray J; Cheung WY; Griesinger F; Subbiah V
JAMA Netw Open; 2022 Nov; 5(11):e2239874. PubMed ID: 36326765
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors of Second-line Immune Checkpoint Inhibitors in Patients With Advanced-stage Non-Small Cell Lung Cancer: A Multicenter, Retrospective Study.
Roh J; Eom JS; Lee MK; Kim J; Jang T; Yoon SH; Son CH; Lee HK; Kim HK; Lee SY; Shin KC; Kim MH
Am J Clin Oncol; 2021 Jul; 44(7):356-360. PubMed ID: 34014843
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan.
Shimokawa M; Kanazu M; Saito R; Mori M; Tamura A; Okano Y; Fujita Y; Endo T; Motegi M; Takata S; Kita T; Sukoh N; Mizuki F; Takenoyama M; Atagi S
Thorac Cancer; 2023 Jun; 14(17):1597-1605. PubMed ID: 37073452
[TBL] [Abstract][Full Text] [Related]
20. Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations Previously Treated with Platinum-Based Chemotherapy and Immunotherapy.
Goldschmidt JH; Tseng WY; Wang Y; Espirito J; Vasudevan A; Silver M; Kwong J; Shah R; Marrett E
Drugs Real World Outcomes; 2024 Jun; ():. PubMed ID: 38896198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
